March 12 (Reuters) - Cancer test maker Grail

said on Thursday that chief executive Bob Ragusa will retire

effective June 1, and the company's president, Josh Ofman, will

take over the helm.

Here are some details:

* Ragusa, who became CEO in 2021, has overseen the cancer

test maker's transition into an independent company after being

spun out of gene sequencing company Illumina ( ILMN ).

* Ofman, who held previous senior roles at Amgen and other

healthcare organizations, has been central to advancing its

flagship cancer-detection test, Galleri, the company said.

* The leadership transition comes at a critical juncture for

Grail as disappointing trial results for Galleri cast doubt on

the test's commercial prospects.

* Last month, the company said routine screening with

Galleri failed to significantly boost early detection or reduce

late-stage diagnoses in a pivotal three-year UK trial.

* "(The CEO change) has been in development for some

time and is unrelated to the NHS trial readout," said Guggenheim

analyst Subbu Nambi.

* Ragusa will remain on Grail's board until his retirement

date and is expected to serve in a senior advisory capacity

through March 2027, the company said.